Chapter 16: Cancer: Cellular Mechanisms

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Welcome to the Deep Dive.

Today we are opening up chapter 16 of one of the most comprehensive texts in molecular biology, launching a systematic exploration into, well, the most personal and pervasive disease facing humanity,

cancer.

Our mission here is to really take you on a complete journey through the cellular and molecular basis of malignancy.

We're going to start with the foundational biology, you know, what makes a cancer cell a rebel, and then move through the groundbreaking experiments that defined oncogenes.

And we'll end with the complex

cutting -edge therapeutic strategies that are really revolutionizing treatment today.

We're going to navigate every major concept, every pathway, every experimental discovery, step by step.

And we begin with a story that I think embodies both the triumph and the tragedy of biological research.

It's centered on the origin of the very first immortal human cell line, keela.

This is the story of Henrietta Lacks.

Exactly.

In 1951, she went to Johns Hopkins for an aggressive cervical cancer.

And while she was there, a sample of her tumor tissue was taken and given to a researcher named George Gay.

Right.

And this was crucially done without her or consent,

a practice that, I mean, it was tragically common for the time, but it's still the core of this deep ethical controversy that is very much alive today.

Absolutely.

And you have to picture Gay's lab.

He had spent decades trying to establish a stable human cell line.

His setup was surprisingly primitive.

I've seen pictures.

It's all hand -blown glass tubes in this thing called a roller drum.

Yes, this roller drum that would slowly rotate the tubes with nutrient broth and tissue samples.

The environment was meticulous, but the results were always, always the same.

Normal cells just wouldn't cooperate.

They wouldn't.

They'd divide, what, maybe 20 to 50 times.

They'd hit a natural limit.

The Hayflick limit.

Right, the Hayflick limit.

And then they just stopped dividing and die off.

That was the single biggest bottleneck in human cell research.

You couldn't do long -term experiments.

You couldn't.

But when Gay put Henrietta Lacks tumor sample into one of those tubes, the cells behaved nothing he'd ever seen.

They just grew profusely, forming a thick sheet over the whole surface.

He divided them into new tubes, and they just kept dividing.

He had done it.

He had created the first truly immortal human cell line named HeLa from her initials.

And the impact of HeLa cells is, I mean, it's almost impossible to measure.

They've been used in something like 74 ,000 studies.

At least.

They were central to testing the first polio vaccine, genetic mapping, virology, medicine.

You name it.

But the ethical questions never went away.

And they keep evolving.

The whole thing blew up again in 2013, right?

It did.

The entire sequenced HeLa genome was released publicly.

And this created enormous privacy concerns for Henrietta Lacks' descendants.

Because their own genetic information could be inferred from that data.

Exactly.

Private medical information about living family members.

It required the National Institutes of Health to step in.

They worked with the Lacks' family and formed a special committee.

So now they control access.

They do.

Anyone who wants to use the HeLa sequence has to get permission from the family.

It's just a stark reminder that even the most abstract discovery is tied to a human story.

It sets a very serious and necessary tone for this whole exploration.

So let's use that to jump into the molecular science section one.

Understanding the basic properties of a cancer cell.

The big takeaway here is that cancer is fundamentally a genetic disease.

That is the absolute foundation of modern oncology.

Cancer is a disease traced back to specific alterations,

mutations, and specific genes.

But it's crucial to make a distinction here.

It's a genetic disease, but not necessarily an inherited one.

Exactly.

That's a common confusion.

In most cases, the defect isn't passed from the parent through the fertilized egg, the zygote.

So where do the mutations come from?

They usually arise from somatic mutations.

These are changes that happen in the DNA of a body cell during an individual's lifetime.

It could be from exposure to a carcinogen or just a random error during cell division.

And once those genetic changes happen, the cell just breaks all the rules.

All of them.

Normal cells operate under very strict constraints.

First, they only divide when they get an external signal.

Second, if they get badly damaged, they undergo programmed cell death apoptosis.

And third, they still put.

They stay in their designated tissue.

And cancer cells reject all three of those rules.

Completely.

That rejection leads to uncontrolled proliferation and the transition to what we call malignancy.

So what's the difference between, say, a localized tumor and the really life -threatening stage?

Well, the uncontrolled growth at first creates a malignant tumor.

This is a mass that actively invades and destroys the healthy tissue around it.

If you look at a

liver section with melanosarcoma, you can see this stark red tumor mass just pushing into and consuming the normal liver tissue.

But that primary tumor isn't usually the deadliest part, is it?

No, the real danger is what comes next.

Metastasis.

This is the process where renegade cancer cells break away from that primary mass.

And get into the bloodstream.

Either the bloodstream or the lymphatic system.

They travel to distant parts of the body and set up shop, establishing these lethal secondary tumors, which are much, much harder to treat.

Despite how devastating it is, we have seen some real clinical progress.

We have.

It's important to remember that.

The American Cancer Society reported a 27 % drop in cancer death rates between 1991 and 2016.

That's huge.

That's mostly from better early diagnosis for specific cancers.

Largely, yes.

Breast, prostate, and colon cancers.

But the fundamental challenge remains the treatments themselves.

They're often described as blunt instruments.

Hemotherapy and radiation.

Right.

They work because cancer cells divide faster than most normal cells, but they lack specificity.

They can't kill only the cancer cells.

This collateral damage to healthy, rapidly dividing tissues is what causes all the terrible side effects.

And it limits the dose you can actually give a patient.

Critically, yes.

It limits the effective dosage.

The holy grail of current research is specificity finding ways to target only the cancer cells.

And to understand that, we can look at how these cells behave outside the body, in vitro.

A really clear sign of malignancy is this loss of growth control.

The key difference is the loss of what's called density -dependent inhibition.

If you grow normal cells in a petri dish, they'll divide until they form a perfect single layer, a monolayer.

And then they just stop.

They stop.

They sense their neighbors, a process called contact inhibition, or they use up the growth factors in the medium, and they just cease growing.

But cancer cells ignore those signals completely.

Absolutely.

If you look at an image comparing them, the malignant cells, under the exact same conditions, just keep piling up on top of one another.

They form these messy, multi -layered clumps we call foci.

They are totally non -responsive.

And this extends to their need for external signals too, right?

This idea of growth factor independence.

Yes.

Normal cells are completely dependent on factors in the serum, like EGF or insulin, to divide.

If you take away the serum, normal cell growth just levels off immediately.

But the cancer cells keep going.

They keep going, with or without those external growth factors.

It shows that their internal cell cycle machinery has become decoupled from the surface receptors.

They're driving themselves forward autonomously.

This autonomy, combined with their other genetic problems, leads to their most famous characteristic,

immortality.

Their potential for unlimited division is, in large part, due to the presence of an enzyme called telomerase.

Telomerase maintains the telomeres, the protective caps on the ends of our chromosomes.

And in most of our normal cells, telomerase is off.

It is.

So the telomeres get shorter with every division, which eventually signals the cell to stop dividing and die.

Cancer cells, by turning telomerase back on, maintain their telomeres and bypass this natural aging process.

And this unlimited division is paired with extreme genetic instability.

Pure chaos.

Cancer cells have highly aberrant chromosome complements, a state we call aneuploidy.

There's a really striking image of this if you look at a karyotype of a breast cancer cell.

It's incredible to see.

A normal karyotype has 22 neat pairs of autosomes and two sex chromosomes.

The cancer cell karyotype is a disaster.

There are extra chromosomes, missing chromosomes.

And they're multicolored.

What does that mean?

The colors show massive numbers of translocations, where large pieces of cells are confused to another.

Any normal cell with this level of damage would immediately trigger apoptosis.

But the cancer cell has lost that ability.

That failure to self -destruct is a critical hallmark.

It is.

And finally, there's a surprising metabolic shift.

Cancer cells seem to prefer an ancient, inefficient energy pathway called glycolysis, even when there's plenty of oxygen around.

We call this aerobic glycolysis.

That seems like a paradox.

Why would they choose the less efficient path?

It's often called the Warburg effect.

And the thinking is that while glycolysis produces less ATP per glucose molecule, it produces it much, much faster.

This might meet the urgent energy demands of a rapidly dividing tumor.

And this has a direct clinical application.

A fantastic one.

Because tumor cells are so hungry for glucose, they take up way more of it than normal cells.

Clinicians exploit this to find tumors using PE scans.

The tumor cells just light up because they're hoarding all the glucose.

And what happens when the tumor outgrows its oxygen supply?

A state called hypoxia.

Hypoxia is actually a major promoter of malignancy.

It activates a transcription factor called HIF.

HIF does two dangerous things.

It induces the formation of new blood vessels to bring in more oxygen, and it promotes the migratory properties of the cells, helping the tumor spread.

So we've outlined the rogue characteristics of the cell itself.

Let's move to section two and look at what causes a normal cell to become malignant in the first place.

And we can start with history way back in 1775 with a British surgeon named Percival Pot.

He made the first clear link between an environmental agent and cancer.

This was the chimney sweeps.

The chimney sweeps, yes.

He definitively linked the high rates of nasal and scrotal cancer to their chronic exposure to soot.

This established the whole concept of carcinogens.

And carcinogens fall into a few categories.

Right.

There are chemicals like those in cigarette smoke, which are either directly mutagenic or are converted into mutagens by our own enzymes.

And then there's radiation, both ionizing and UV radiation, which damages DNA directly.

But the cause isn't always a chemical or radiation.

We also have tumor viruses.

The viruses are broadly split into DNA tumor viruses and RNA tumor viruses, which we call retroviruses.

The key mechanism here is that these viruses carry genes called oncogenes, whose products interfere with the cell's normal growth regulating machinery.

They hijack the cell.

They hijack the cell.

Now, while viruses were hugely important for research, they're only directly linked to maybe 20 % of human cancers worldwide.

And even then, the virus usually just increases the risk, right?

It's not the sole cause.

Precisely.

For example, HPV, the human papilloma virus, is linked to nearly all cervical cancers.

But the vast majority of women infected with HPV never develop cancer.

The virus is a major risk factor, but other things have to go wrong, too.

And we see other links like hepatitis B and liver cancer, Epstein -Barr, and certain lymphomas.

Yes.

But beyond these specific viral links, there's a newer, broader focus now on the connection between cancer and chronic inflammation.

How can inflammation, which is our body's healing response, actually cause cancer?

Well, we know some gastric lymphomas are tied to a bacterium, Helicobacter pylori.

And the newer insight is that many cancers associated with chronic infection are actually driven by the state of chronic inflammation the pathogen creates.

So it's the constant inflammatory signals that are the problem.

Exactly.

Conditions like inflammatory bowel disease significantly raise the risk of colon cancer.

The continuous release of these signals seems to promote cell proliferation and the accumulation of mutations.

This leads us to epidemiology, which must be incredibly hard.

Yeah.

Humans are exposed to so many things over so many decades.

It's very hard to isolate single variables, but the undeniable importance of environment and lifestyle, especially diet, comes through so clearly in migration studies.

Tell us about those.

So researchers track Japanese individuals who migrated to Hawaii.

In Japan, gastric cancer rates are high.

But as these migrants adopted a Western diet and lifestyle, their rate of gastric cancer went down.

Other cancers went up.

Yes.

Their rates of breast and colon cancer started to rise, matching the rates in their new home.

It's powerful proof that environment and lifestyle can often override genetic heritage.

And within that lifestyle, we know obesity and diet are huge factors.

Huge.

Cancer rates are consistently higher in obese individuals.

A lot of research has focused on how elevated levels of insulin and IGF -1 in obese individuals act as growth promoters.

But conversely, there are protective compounds in food, too.

There are.

Isoflavones in soy, sulfurathans in broccoli, EGCG in green tea.

And it's remarkable that even common drugs can have a prevented effect.

Like aspirin.

Like aspirin.

Long -term use of NSIIs like aspirin is associated with a marked decrease in colon cancer risk.

The thinking is that it inhibits an enzyme called COX2, which is involved in an inflammatory growth pathway in the gut.

This idea that simple chemical changes can drive malignancy leads us right into section three, experimental pathways.

This is such a crucial historical section that reveals the cellular mechanism of oncogenes, and it has to start with Peyton Russ in 1911.

Bruce's work was so far ahead of its time.

He was working with a sarcoma in chickens, and he performed this landmark experiment.

He took tumor material, ground it up, and passed it through a filter, fine enough to remove all cells and bacteria.

So he just had this cell -free liquid.

A cell -free filtrate.

He injected that steroliquid into healthy hens, and they developed the sarcoma.

He proved the tumor was being transmitted by a filterable agent, a virus.

It was a monumental discovery that was mostly ignored for decades.

Okay, fast forward to the 1960s.

Similar RNA tumor viruses are being studied, but there's a huge conceptual problem.

How does an RNA genome get reliably passed down from a parent cell to its daughter cells?

Howard Timmons came up with a hypothesis.

He suggested there had be a DNA intermediate, which he called a provirus.

The viral RNA would be used as a template to make a DNA copy, which would then integrate into the host's genome.

But that would require an enzyme that could make DNA from an RNA template.

That violates the central dogma of biology.

It did, and in 1970, David Baltimore and independently Timmons himself discovered that very enzyme, RNA -dependent DNA polymerase, or as we all know it, reverse transcriptase.

Baltimore's experiment proving this is just.

It's one of the pillars of modern science.

Can we walk through it?

Absolutely.

He incubated purified virus particles with the building blocks for DNA, including a radioactively labeled one, and he found that the preparation was incorporated in the label into a large molecule.

So he knew something was being made.

How did he prove it was DNA?

He used molecular scissors.

The new product was completely destroyed by DNAs, which cuts DNA, but it was unaffected by RNAs, which cuts RNA.

And crucially, if he treated the virus with RNAs before the reaction, nothing was made.

So the RNA had to be the template.

The RNA was the template for the DNA product.

That experiment established the provirus concept and turned the central dogma on its head.

And once we had reverse transcriptase, the race was on to find the transforming gene itself.

Rose's virus was now called avian sarcoma virus, or ASV.

Right, and researchers found mutant strains of ASV that could replicate but couldn't transform cells anymore.

The part of the genome that was deleted was named SRC for sarcoma.

And this set the stage for the big discovery from Varmus and Bishop.

It did.

They devised this brilliant strategy.

They used reverse transcriptase to make a radioactive DNA copy of the entire normal viral genome.

They called it cDNA -SARC.

Then they took this labeled probe and tried to match it up or hybridize it to the RNA from the defective genes, the ones missing the sarcoma.

So the bits of the probe that didn't find a match had to be the SRC sequences.

Precisely.

They isolated those non -hybridizing fragments, and then came the true conceptual leap, the monumental insight.

They used this purified SRC probe and tested it against the DNA from normal, uninfected chicken cells.

And it hybridized perfectly, not just to chicken DNA, but to the DNA of all birds they tested, and incredibly to the DNA of all vertebrate classes, including mammals.

Wait, hold on.

So the cancer -causing gene wasn't some unique viral invention.

No.

It was a normal, conserved cellular gene that the virus had just picked up.

Exactly.

That changed everything.

The virus had simply hijacked a normal cellular gene, a proto -oncogene.

The cellular version was named CSRC, and its conservation across evolution meant it had to be doing something fundamentally important in normal cells.

So the next puzzle was, what does the protein product PP60 -SCRC actually do?

They found it was a protein kinase.

It could transfer a phosphate group from ATP onto other proteins.

But the biggest surprise was where it put the phosphate.

All the kinases they knew at the time targeted serine or threon residues.

All of them.

But PP60 -SCRC was a tyrosine protein kinase.

It phosphorylated tyrosine residues.

This discovery opened up an entirely new field of cell signaling.

And the reason the viral version, VSRC, caused cancer was just that it was always on, always hyperactive, compared to the carefully regulated cellular version.

That's it.

Unregulated activity of a normal cellular protein was enough to drive malignancy.

And this viral work gave us the tools to understand human cancers that weren't caused by viruses at all.

Yes.

Robert Weinberg's lab showed that you could take DNA from chemically transformed mouse cells and use it to transform normal cells.

This proved chemical carcinogens work by altering nucleotide sequences to create oncogenes.

And a human connection came in 1981.

It did.

DNA from human bladder cancer cells was shown to transform mouse cells.

This was the first hard evidence that activated arcogenes were directly involved in human cancer.

And when they isolated that human oncogene, it turned out to be a familiar one.

It was a version of the Ras gene, and the mechanism of its activation was stunningly specific.

It was a single base substitution,

a single typo.

Just one letter change in the DNA code.

One letter.

A guanine was changed to a thymidine.

This caused one amino acid, glycine, to be replaced by valine.

And that single change was enough to jam the Ras protein's accelerator pedal to the floor permanently.

So the final implication is that viruses gave us the window to understand that human cancers arise from tiny specific genetic mistakes in our own cellular genes.

That is the conceptual insight that has driven the last 30 years of cancer research.

A phenomenal chain of discoveries.

Let's use that foundation to move into Section 4, continuing with cancer as a genetic disorder and starting with the idea of multistep tumor genesis.

Right.

Cancer is statistically rare because it's not a single event.

It requires a whole progression of permanent genetic and, importantly, epigenetic alterations that accumulate over decades.

Okay, what do you mean by epigenetic?

Those aren't mutations in the DNA sequence itself.

Correct.

Epigenetic changes are alterations in gene expression that don't change the DNA code.

It's usually things like changes to the chromatin structure or DNA methylation patterns that can, for example, turn a gene on or off.

And these changes are permanent?

They are heritable.

Once they happen, they're stably passed down to all the daughter cells, locking in the malignant characteristics just as firmly as a mutation would.

And for a tumor to even get started, the cell of origin has to be one that can divide for a long time.

Exactly.

That's why we often focus on stem cells or progenitor cells.

They have the longevity to accumulate all the necessary hits required to break through all the layers of cellular control.

And we can see these accumulating changes in the appearance of the cells themselves, the histology.

We can.

The pap smear is a perfect example of diagnostics designed to catch these early cancerous changes.

Normal cervical cells are uniform with small nuclei.

But pre -cancerous cells, or carcinoma in situ, have weird shapes and abnormally large nuclei, reflecting that genetic chaos inside.

So before we get into the specific genes, let's formally define the two main players.

The tumor suppressor genes, TSGs,

and the oncogenes.

The TSGs are the breaks.

They encode proteins that restrain cell growth and maintain genetic stability.

They're recessively acting, which means you have to lose the function of both copies of the gene, both alleles, to lose the protection.

And the oncogenes are the accelerators.

They are.

They're derived from our normal proto -oncogenes.

They encode proteins that promote cell growth and they're dominantly acting.

A gain -of -function mutation in just one copy is usually enough to start pushing the cell toward cancer.

Let's start with the breaks.

And the first key break we have to talk about is the RB gene associated with retinoblastoma.

The RB gene is famous because it led to Alfred Knudsen's brilliant two -hit hypothesis.

He used it to explain why there were two forms of the disease.

Sporadic and familial.

In the familial cases, the first hit is inherited.

Exactly.

The individual inherits one bad copy of the RB gene, so every cell in their body is already halfway to cancer.

They only need one more spontaneous mutation in their other, good copy for a retinal cell to lose the break completely and form a tumor.

And the protein, PRB, is the master regulator of the cell's commitment point, the G1S checkpoint.

How does it work?

Think of PRB as a molecular clamp.

In the G1 phase of the cell cycle,

unphosphorylated PRB binds tightly to a transcription factor called E2F.

This complex acts as a repressor, silencing the genes needed for the next phase, S phase.

So it holds the cell back from dividing.

It does.

To commit to division, the cell has to release that clamp, and it does that by using enzymes called CDTase to phosphorylate PRB.

This phosphorylation changes PRB shape, forcing it to let go of E2F.

And once E2F is free, it flips from a repressor to an activator, turning on all the genes needed for DNA synthesis.

The cell barrels into S phase.

If you lose the RB gene, you lose that clamp, there's no break.

If PRB is a critical break, then TP53 is the ultimate guardian.

It's the most commonly mutated gene in human cancer.

It is.

Mutated in about 50 % of all human tumors.

It encodes the P53 transcription factor.

Loss of P53 is almost always correlated with a much poorer prognosis.

So what does P53 do when a cell is stressed, say, by DNA damage?

P53 is the cell's emergency responder.

Once activated by DNA damage, it does two main things.

First, it triggers a G1 arrest.

It turns on a gene for a protein called P21, which is a CDK inhibitor.

This stops the cell cycle to give it time to repair the DNA.

And if the damage is too severe?

Then it initiates apoptosis, cell suicide.

It turns on genes like BAX or directly interacts with other proteins at the mitochondria to trigger the self -destruct sequence.

So a cell without P53 can't arrest and it can't die in response to damage.

It can't.

And this has profound clinical implications.

Tumors with non -functional P53 are highly resistant to traditional treatments like chemotherapy and radiation because those treatments work by causing so much DNA damage that a normal cell would commit suicide, but these cells can't.

Beyond RB and P53, let's quickly touch on a few other key tumor suppressors.

Okay.

First, APC.

Loss of APC is the initial hit in most colon tumors.

It helps regulate a key growth pathway called WUNT.

Then there are the breast cancer genes.

BRCA1 and BRCA2.

These proteins are absolutely central to high fidelity DNA repair.

When you lose them, the cell can't fix double strand breaks properly, leading to massive chromosomal instability.

And finally, PTAEE.

PTN is a counterswitch.

It's a phosphatase that reverses the action of a major pro -survival pathway called the PI3KAKT pathway.

So loss of PTN leads to excessive cell survival signals, giving a huge advantage to a cancer cell.

Okay.

We've covered the breaks.

Now let's look at the different functional classes of proteins encoded by proto -oncogenes.

We can group them functionally.

First, you have growth factors and their receptors.

Things like the cis -oncogene, which causes a cell to make its own growth factor and stimulate itself in a loop.

Then there are cytoplasmic protein kinases.

Right.

Key signal relayers.

This includes REF, which heads the critical MAP kinase cascade, and SRC, the tyrosine kinase we discussed earlier.

And transcription factors.

MYC is the quintessential example.

It drives the expression of hundreds of genes needed for growth and proliferation.

It's often activated by gene amplification.

The cell just makes way too many copies of it.

There are also newer categories, like epigenetic modifiers and metabolic enzymes.

Yes.

Mutations in these genes don't directly push growth, but they change the whole landscape of gene regulation or cellular metabolism in a way

A key example is the IDH1 enzyme, where a mutation produces an oncomatabolite that disrupts normal cell function.

And finally you have apoptosis inhibitors.

Right.

Any protein that blocks cell death is inherently oncogenic.

The classic one is BCL2.

Its overexpression allows abnormal cells that should have died to survive and proliferate, which is a hallmark of certain lymphomas.

So we have all these different genes, but it's really a pathway disease.

The different mutations converge on a small number of core cellular processes.

That is the most critical insight for drug development.

While you might find hundreds of different genes mutated across all cancers, they all tend to mess up the same 20 or so core pathways.

The P53 pathway and the PI3K pathway are the two most common.

And before we get to treatment, we have to mention gene expression analysis using microarrays, which totally changed how we classify and predict tumor behavior.

Microarrays are incredible tools.

They're basically glass slides with thousands of spots, each containing a known gene sequence.

You can take the mRNA from a patient's tumor, label it fluorescently, and see which genes are turned on or off and at what level.

And this has real clinical value.

Immense value.

For prognosis especially.

In breast cancer, researchers identified a specific 70 gene expression profile that can predict a patient's likelihood of survival.

So you can tailor the treatments.

Exactly.

A patient with a poor prognosis signature can be treated much more aggressively.

But just as importantly, a patient with a good prognosis signature can be spared unnecessary debilitating chemotherapy.

It's the beginning of truly personalized medicine.

That precision brings us to Section 5, starting with the mainstay of treatment.

Therapeutic radiation.

Over 60 % of cancer patients receive radiation.

It's delivered either from an external beam using a machine called a Lenac, or internally, which is called brachytherapy, where radioactive material is placed right next to the tumor.

And the mechanism is just brute force damage?

Pretty much.

It works by causing extensive DNA damage, specifically double -stranded breaks, and by generating damaging free radicals.

This overwhelming damage forces the cell toward death either through apoptosis or by just failing catastrophically when it tries to divide.

Moving from machines to nature.

Section 6 covers the surprising number of plant -based chemotherapies.

It's a fascinating history.

From the Madagascar periwinkle, we got the vinka alkaloids, like vincristine.

These drugs work by binding to tubulin and causing microtubules to fall apart, which halts cell division.

And from the Pacific eutreide, we got taxil.

Taxil, or pacl -taxil, became one of the best -selling chemo drugs ever.

And it works by the exact opposite mechanism.

Instead of destroying microtubules, it stabilizes them, freezing them in place.

This also prevents cell division.

And other plant derivatives target different machinery, like topoisomerases.

Correct.

Compounds from the Chinese happy tree led to drugs that inhibit topoisomerase I, and those from the May apple inhibit topoisomerase II.

Both of these enzymes are essential for managing DNA during replication, so blocking them causes fatal DNA breaks.

These systemic treatments were the standard for decades.

In Section 7, we get to the modern era.

Strategies for combating cancer with a goal being targeted therapies.

Exactly.

Moving beyond that brute force approach,

the new strategies aim to attack only cancer cells by hitting a specific aberrant protein or exploiting a unique genetic vulnerability.

It's a concept we call oncogene addiction.

Let's start with immunotherapy.

Okay, we can split this into passive and active.

Passive immunotherapy involves giving the patient manufactured antibodies.

A great example is Herceptin, which targets the HER2 receptor.

Which is overexpressed in about a quarter of breast cancers.

Right.

The antibody binds to that receptor and shuts it down.

We also have amazing new things like bispecific antibodies, which are engineered to act as a bridge.

One end grabs the cancer cell, the other end grabs one of the patient's own T cells, and it forces the T cell to attack.

So that's the passive approach.

Yeah.

What about active or active immunotherapy?

This is about stimulating the body's own immune response.

The challenge is that tumors are clever.

They evade the immune system by expressing proteins on their surface, like PD -L1, that bind to receptors on T cells, like PD -1.

This binding is an off switch for the T cell.

So the therapy is to block that off switch.

You got it.

It's called immune blockade.

We use antibodies that block either PD -1 or PD -L1.

This takes the breaks off the T cells, unleashing them against the tumor.

It's been a massive success in melanoma and lung cancer.

And then there's the most personalized approach of all, Tera T cell therapy.

Tera T cells are a true revolution.

You take T cells out of the patient and you genetically engineer them in the lab to produce a custom designed receptor, a chimeric antigen receptor, or CERR, that will recognize a specific protein on that patient's tumor.

Then you put the supercharged cells back in.

And they go on a search and destroy mission.

It has shown absolutely remarkable success

especially in kids.

Let's turn back to chemical inhibitors and that idea of oncogene addiction.

Right.

The idea that a tumor can become so dependent on one single faulty protein that if you inhibit it, the whole tumor collapses.

The landmark success that proved this was the drug Gleevec for chronic myelogenous leukemia, or CML.

CML is driven by a single fusion protein, BCRABL.

Which is a hyperactive tyrosine kinase.

Gleevec was designed to fit perfectly into the inactive form of that kinase, preventing it from ever turning on.

The results were spectacular.

It put nearly all CML patients into sustained remission.

But as is often the case, resistance emerged.

It did.

The tumor cells evolved.

They acquired secondary mutations in the ABL gene that stopped Gleevec from being able to bind.

This spurred the development of second and third generation drugs and pushed the field toward using combination therapies from the start.

We saw a similar story with Xelboraf for melanoma.

A very similar story.

Xelboraf targets a specific mutation, BRAFE600E.

The initial response is often dramatic tumors just melt away.

But resistance emerges, usually within months, because the tumor finds a bypass pathway to reactivate the signals downstream.

This all underscores the absolute necessity of genetic screening before starting treatment.

It is non -negotiable now.

You have to know the specific genotype of the tumor.

You only give a drug like Xalcori to the small subset of lung cancer patients who have the specific EML4 -ALK fusion protein.

Otherwise, it's just guesswork.

There's also this incredibly clever approach called synthetic lethality.

This is so elegant.

It turns a cancer cell's weakness into a fatal flaw.

The classic example is using PRP1 inhibitors in tumors that are deficient in the BRCA genes.

So because the tumor cells have already lost the BRCA DNA repair pathway.

They become completely dependent on this other repair pathway that uses PRP1.

So if you then use a drug to inhibit PRP1, you take out their last line of defense, the cancer cells die.

But the normal cells, which still have their BRCA genes, are unharmed.

Exactly.

It's a way to specifically kill cancer cells because they have lost a tumor suppressor.

And our final strategy goes back to the tumor's need for a blood supply, inhibiting angiogenesis.

Right.

The idea of starving the tumor by cutting off its blood supply.

Tumors secrete a factor called VEGF to stimulate new blood vessel growth.

The drug Avastin is an antibody that blocks VEGF.

And how has that worked out?

It's had modest success.

It can prolong life for a few months in some cancers, usually when combined with chemo.

But the spectacular results seen in mice haven't really translated into cures for humans, and the initial excitement has waned a bit.

So at the end of all this, the best strategy still remains the most basic one.

Early detection.

Absolutely.

There's often a window of a decade or more for many common cancers.

The screening procedures we have now, mammograms, colonoscopies, are lifesavers.

The future is finding biomarkers in the blood that let us catch cancer even earlier.

That concludes our incredibly dense, but I think essential, deep dive into the cellular and molecular biology of cancer.

We've seen it as a genetic, multi -hit disease driven by the failure of tumor suppressors like P53 and the activation of oncogenes like RAS.

And we've mapped this huge shift from generalized brute force chemotherapy to these highly personalized, targeted therapies that exploit specific molecular vulnerabilities.

So if we look ahead, the challenge seems to be moving beyond treating cancers by their tissue of origin.

It's not just breast cancer anymore.

It's not.

It's about treating a cancer based on its specific, unique combination of mutated cellular pathways.

Which means the future is really about reading an individual's mutational landscape and then crafting these customized drug cocktails to block all the critical pathways at once.

That customization is, I think, the only way forward in neutralizing this incredibly complex and rapidly evolving adversary.

Thank you for joining us for this comprehensive deep dive.

We really hope this exploration provides you with a robust understanding of the molecular reality of cancer.

My pleasure.

As always, we encourage you to keep learning and stay curious.

Take care.